Secukinumab in the Treatment of Noninfectious Uveitis

Secukinumab in the Treatment of Noninfec

Secukinumab in the Treatment of Noninfectious Uveitis: Results of Three Randomized, Controlled Clinical Trials

✍ Dick, Andrew D.; Tugal-Tutkun, Ilknur; Foster, Stephen; Zierhut, Manfred; Meliss 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 486 KB

[Developments in Ophthalmology] New Trea

[Developments in Ophthalmology] New Treatments in Noninfectious Uveitis Volume 51 || Rituximab for Noninfectious Uveitis

✍ Miserocchi, E.; Modorati, G.; Foster, C.S. 📂 Article 📅 2012 🏛 S. KARGER AG 🌐 English ⚖ 153 KB

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intrao

[Developments in Ophthalmology] New Trea

[Developments in Ophthalmology] New Treatments in Noninfectious Uveitis Volume 51 || The Gold Standard of Noninfectious Uveitis: Corticosteroids

✍ Miserocchi, E.; Modorati, G.; Foster, C.S. 📂 Article 📅 2012 🏛 S. KARGER AG 🌐 English ⚖ 543 KB

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intrao

Infliximab for the Treatment of Refracto

Infliximab for the Treatment of Refractory Noninfectious Uveitis

✍ Kruh, Jonathan N.; Yang, Paul; Suelves, Ana M.; Foster, C. Stephen 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 319 KB

[Developments in Ophthalmology] New Trea

[Developments in Ophthalmology] New Treatments in Noninfectious Uveitis Volume 51 || Anti-Tumor Necrosis Factor-a Agents in Noninfectious Uveitis

✍ Miserocchi, E.; Modorati, G.; Foster, C.S. 📂 Article 📅 2012 🏛 S. KARGER AG 🌐 English ⚖ 313 KB

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intrao

Risk of Hypotony in Noninfectious Uveiti

Risk of Hypotony in Noninfectious Uveitis

✍ Daniel, Ebenezer; Pistilli, Maxwell; Pujari, Siddharth S.; Kaçmaz, R. Oktay; Nus 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 736 KB